TriSalus Life Sciences (TLSI) EBT (2021 - 2026)

TriSalus Life Sciences' EBT history runs 6 years deep, the most recent figure standing at $1.5 million for Q1 2026.

• On a quarterly basis, EBT rose 114.88% year-over-year to $1.5 million in Q1 2026; TTM through Mar 2026 was -$27.3 million, a 0.37% change from a year earlier, with the FY2025 full-year figure at -$39.2 million, down 30.56% from the prior year.
• EBT advanced to $1.5 million in Q1 2026 per TLSI's latest filing, from -$9.8 million in the prior quarter.
• Across five years, EBT topped out at $2.8 million in Q1 2022 and bottomed at -$35.6 million in Q4 2023.
• The 5-year median for EBT is -$8.3 million (2025), against an average of -$9.0 million.
• Biggest YoY gain for EBT was 958.66% in 2022; the steepest drop was 878.25% in 2022.
• Year by year, EBT stood at -$22.5 million in 2022, then slumped by 58.14% to -$35.6 million in 2023, then soared by 71.63% to -$10.1 million in 2024, then climbed by 3.52% to -$9.8 million in 2025, then jumped by 115.82% to $1.5 million in 2026.
• Per Business Quant, the three latest TLSI EBT figures stand at $1.5 million (Q1 2026), -$9.8 million (Q4 2025), and -$10.8 million (Q3 2025).